Immuneering Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immuneering Corporation (IMRX) Immuneering Corporation, a clinical-stage oncology company, develops novel small molecule therapeutics targeting the RAS/RAF/MEK signaling pathway for patients with advanced solid tumors; its lead product candidate atebimetinib (IMM-1-104), an oral once-daily deep cyclic MEK inhibitor, advances through Phase 2a trials in pancreatic cancer, melanoma, and non-small cell lung cancer (NSCLC), including monotherapy and planned combinations with chemotherapy, PD-1 inhibitors, BRAF inhibitors, and KRAS G12C inhibitors under clinical supply agreements with Eli Lilly and Regeneron; IMM-6-415, an oral twice-daily deep cyclic MEK inhibitor, progresses in Phase 1/2a trials for RAS- or RAF-mutant solid tumors; the company leverages its proprietary Disease Canceling Technology platform, integrating bioinformatics, machine learning, and human data, to design selective inhibitors that modulate signaling dynamics for improved tolerability across broad patient populations. Immuneering Corporation operates primarily in the United States from its headquarters at 245 Main Street, Second Floor, Cambridge, Massachusetts; founded in 2008 by computational biology experts including CEO Benjamin Zeskind alongside MIT researchers Forest White and Doug Lauffenburger, the firm shifted from bioinformatics services around 2015 to internal drug development following Series A funding in 2019 and its 2021 Nasdaq IPO that raised approximately $129 million. In September 2025, Immuneering Corporation completed a $175 million public offering of 18.96 million Class A shares at $9.23 per share, concurrent with a $25 million private placement to Sanofi purchasing 2.71 million shares at the same price, generating approximately $200 million in gross proceeds to fund preclinical and clinical programs through at least 2029 including a planned pivotal Phase 3 trial for atebimetinib; these transactions, underwritten by Leerink Partners and Oppenheimer & Co. with a 30-day overallotment option, followed a shelf registration effective in August 2025 and an August funding round of nearly $25 million from nine investors.
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation: Updates Inbound At The End Of The Month
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering to Present at the Leerink Global Healthcare Conference
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
Insider Buying: Immuneering (NASDAQ:IMRX) Insider Buys $10,501.86 in Stock
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update